John Maraganore is the founding CEO of Alnylam Pharmaceuticals, where he pioneered RNA interference (RNAi) therapeutics as a new class of medicines. Under his leadership, Alnylam invested over $2.5 billion in RNAi development across nearly two decades, culminating in the first regulatory approval of RNAi-based therapies. Based in Boston, he is now a bioentrepreneur-at-large with recognized expertise in RNAi biotechnology.

‌